Evaluation of clinical and ultrasonographic parameters in psoriatic arthritis patients treated with adalimumab: a retrospective study.
OBJECTIVE
The aim of this study was to evaluate clinical and US-PD parameters in PsA during adalimumab treatment.


METHODS
A retrospective study has been conducted in forty patients affected by moderate-to-severe peripheral PsA. Clinical, laboratory, and US-PD evaluations were performed at baseline, after 4, 12, and 24 weeks of treatment. They included erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), visual analogue scale (VAS), Health Assessment Questionnaire (HAQ) modified for Spondyloarthritis, Psoriasis Area Severity Index (PASI) score, the 28-joint Disease Activity Score (DAS 28), and US-PD assessment. US-PD findings were scored according to a semiquantitative scale (ranging 0-3) for synovial proliferation (SP), joint effusion (SE), bone erosions (BE), and PD.


RESULTS
Data obtained for clinical, laboratory findings and US-PD evaluation showed statistical significant improvement in all the measures performed except for BE. A significant parallel decrease in SE, SP, and PD values were demonstrated.


CONCLUSIONS
This study demonstrated that US-PD is a valid technique in monitoring the response to adalimumab in moderate-to-severe PsA.
Department of Dermatology, University of Rome Tor Vergata, Viale Oxford 81, 00133 Rome, Italy. miriam teoli@libero.it
M
M
Teoli
A
A
Zangrilli
M S
MS
Chimenti
M
M
Talamonti
M
M
Bavetta
D
D
Graceffa
R
R
Perricone
S
S
Chimenti
D000068879:Adalimumab; D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000009:adverse effects; D015535:Arthritis, Psoriatic / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D001799:Blood Sedimentation; D001862:Bone Resorption / Q000000981:diagnostic imaging / Q000473:pathology; D002097:C-Reactive Protein / Q000378:metabolism; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012720:Severity of Illness Index; D013583:Synovial Membrane / Q000000981:diagnostic imaging / Q000473:pathology; D014463:Ultrasonography
D000894:Anti-Inflammatory Agents, Non-Steroidal; D061067:Antibodies, Monoclonal, Humanized; D002097:C-Reactive Protein; D000068879:Adalimumab